Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Forges Ahead With Taspoglutide Despite Other GLP-1 Cancer Signal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche is forging ahead with its glucagon-like peptide-1 analog taspoglutide despite reports of adenomas (benign tumors) in animal studies and the stumbling block Novo Nordisk hit with its competing type 2 diabetes product Victoza (liraglutide) due to a thyroid cancer signal in animals

You may also be interested in...

No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval

Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts